ABSTRACT
Histologic confirmation of cardiac sarcoidosis (CS) is challenging. When taken into account of either the invasive nature or potential false negativity of the endomyocardial biopsy, imaging methods represent as a major alternative to establish a clinical diagnosis. Among the imaging methods, the use of fluorine-18-fluorodeoxyglucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) which detects active inflammation in CS is becoming widespread. Recently, F-18 FDG PET has been identified as one of the new diagnostic criteria in CS, by the Heart Rhythm Society. For diagnosis, a combination of both myocardial perfusion and inflammation findings should be interpreted visually and/or semiquantitatively. Yet, the precision of diagnostic accuracy has been limited by lack of an adequate reference standard. This procedure guideline presents current literature defining the role of F-18 FDG PET in the diagnosis and management of CS along with technical details and recommendations about imaging protocol and interpretation.
Keywords:
F-18 FDG PET/CT, cardiac sarcoidosis, inflammation
References
1
Bernstein M, Konzelman FW, Sidlick DM. Boeck’s sarcoid: report of a case with visceral involvement. Arch Intern Med 1929;4:721-734.
2
Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-1435.
3
Koiwa H, Tsujino I, Ohira H, et al. Images in cardiovascular medicine: Imaging of cardiac sarcoid lesions using fasting cardiac F-18 fluorodeoxyglucose positron emission tomography: An autopsy case. Circulation 2010;122:535-536.
4
Lagana SM, Parwani AV, Nichols LC. Cardiac sarcoidosis: a pathology focused review. Arch Pathol Lab Med 2010;134:1039-1046.
5
Ward EV, Nazari J, Edelman RR. Coronary artery vasculitis as a presentation of cardiac sarcoidosis. Circulation 2012;125:344-346.
6
Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC Expert Consensus Document on the Role of (18)F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring. J Nucl Med 2017;58:1341-1353.
7
Diagnostic standard and guidelines for sarcoidosis. Japanese J Sarcoidosis Other Granulamatous Disord 2007;27:89-102.
8
Birnie D, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-1323.
9
Mc Ardle BA, Leung E, Ohira H, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:297-306.
10
Leone O, Veinot JP, Angelini A, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012;21:245-274.
11
Schatka I, Bengel FM. Advanced imaging of cardiac sarcoidosis. J Nucl Med 2014;55:99-106.
12
Youssef G, Leung E, Mylonas I, et al. The use of F-18 FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-248.
13
Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with F-18-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-941.
14
Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines/SNMMI procedure Standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol 2016;23:1187-1226.
15
Osborne MT, Hulten EA, Murthy VL, et al. Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J Nucl Cardiol 2017;24:86-99.
16
Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial F-18-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2015;23:244-252.
17
Asmal AC, Leary WP, Thandroyen F, et al. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531-533.
18
Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.
19
Kumita S, Yoshinaga K, Miyagawa M, et al. Recommendations for F-18-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol 2019;26:1414-1433.
20
Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on FDG PET tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-1543.
21
Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging 2016;9:000867.
22
Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-336.
23
Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925-939.
24
Schildt JV, Loimaala AJ, Hippeläinen ET, Ahonen AA. Heterogeneity of myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake is a typical feature in cardiac sarcoidosis: A study of 231 patients. Eur Heart J Cardiovasc Imaging 2018;19:293-298.
25
Osborne MT, Hulten EA, Singh A, et al. Reduction in F-18-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-174.
26
Bartlett ML, Bacharach SL, Voipio-Pulkki LM, et al. Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects. J Nucl Med 1995;36:188-195.
